Remote Ischemic Conditioning (RIC)

Brief episodes of no blood flow (ischemia) in a limb followed by resumed blood flow (reperfusion).

Repetitive ischemia/reperfusion (e.g. 4 cycles of 5 minutes ischemia/5 minutes reperfusion) applied to a limb induces REMOTE protection of all solid organs against potentially lethal ischemia/reperfusion injury.

Clinical trials have shown that these ‘preconditioning’ mechanisms of metabolic protection result in robust clinical benefit to the patient, in both the short and the long-term.

View Clinical Trials

RIC Markets

RIC has proven efficacy in acute care settings, including treatment of patients in the ambulance or emergency room, or before cardiac procedures (surgery or other cardiac interventions). The simple to use autoRIC™ Device also allows for patient administered treatment in the home for chronic disease treatment.

$2 Billion Acute Market
Hospital and pre-hospital settings

$4-6 Billion Chronic Market
Heart Failure, Stroke, Home & Public settings

Explore Acute Hospital Sub-Markets

Automating RIC with
The CellAegis autoRIC® Device

The autoRIC® Device delivers Remote Ischemic Conditioning (RIC) to the patient through a non-invasive and automated application.

The autoRIC® Device is highly portable and time‐efficient, delivering four cycles of simple‐to-administer treatment in less than 40 minutes, freeing up valuable healthcare resources. Device operation is simple and compatible with current standard‐of‐care treatments. RIC delivery is consistent, reliable, and cost-effective.


Learn more about the autoRIC® Device